Parkinson DiseasePARKANCT04322461
Effect of Exercise, Endocannabinoids and Ketones on Cerebral Metabolism in a Cognitive Disorders Population
A study testing Betaquik MCT supplement in people with Parkinson Disease and Alzheimer Disease, run by Université de Sherbrooke at 1 site in Canada.
Trial summary
A two months intervention in which two groups of cognitive disorders, Parkinson and Alzheimer's disease, will receive 50g/day of a commercial MCT supplement combined with supervised aerobic exercise 3 times/week. Read more about this study
- Who is it for?
- Ages 60 years and older
- Conditions the study is for
- Parkinson Disease, Alzheimer Disease
- What is being tested?
- Betaquik MCT supplement
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 14 participants
- Where
- 1 siteCanada
- Study dates
- 1 May 2022to 27 May 2024
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 60 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Alzheimer's or parkinson disease diagnostic
- Stable medication associated with the disease
- Able to consent
- Presence of an accompanying person for the first and last visit.
- Ability to read and talk in French
Who cannot join
- MMSE < 20
- MCT or coconut oil supplementation
- Coconut allergy
- Cannabis, THC or CBD consumption
- Excessive alcohol consumption
- Physical activity 3x/week
Show all 10Show fewer
- Presence of an metallic object in the body
- Impossibility to lay in dorsal decubitus for 40 minutes
- Cardiac disease
- Any uncontrolled disease that could interfer with the project.
Trial locations and contacts
1 site in 1 country.
Canada1 site
Centre de recherche sur le vieillissement
Sherbrooke, Quebec, J1H 4C4
About this study
Official title: Effect of Exercise, Endocannabinoids and Ketones on Cerebral Metabolism in a Cognitive Disorders Population : Pilot Project PARKA
A two months intervention in which two groups of cognitive disorders, Parkinson and Alzheimer's disease, will receive 50g/day of a commercial MCT supplement combined with supervised aerobic exercise 3 times/week. Cognition and ketones will be assess before and after the intervention, along with endocannabinoids plasma concentrations.
- Conditions
- Parkinson Disease, Alzheimer Disease
- Being tested
- Betaquik MCT supplement
- Keywords
- Alzheimer, Parkinson, Ketones, medium chain triglycerides, cognition, brain
- Medical subject headings
- Parkinson Disease, Alzheimer Disease, Ketosis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Betaquik MCT supplementDietary supplement
50g/day divided in 3. Breakfast, lunch and dinner
| Study group | Role | What they receive |
|---|---|---|
| Parkinson disease | Experimental | 2 months intervention with 50g/day of a commercial MCT supplement combine with supervised aerobic exercise 3x/week. Receives: Dietary Supplement: Betaquik MCT supplement |
| Alzheimer's disease | Experimental | 2 months intervention with 50g/day of a commercial MCT supplement combine with supervised aerobic exercise 3x/week. Receives: Dietary Supplement: Betaquik MCT supplement |
What is being measured
The primary outcome is the main question the study is designed to answer.
Cognition
Measure of cognition with CANTAB
Measured: 2 months, evaluation before and after intervention
Ketones
Measurement of ketones concentrations
Measured: 2 months, evaluation before and after intervention
Secondary outcomes (1)
Endocannabinoids
Endocannabinoids plasma concentration
Measured: 2 months, evaluation before and after intervention
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted26 Mar 2020
- Study start1 May 2022
- Primary completion27 May 2024
- Study completion27 May 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Parkinson DiseaseStudies of the same condition, open and under way.
- More trials run by Université de SherbrookeThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 14 participants (actual)
Sponsor and investigators
- Lead sponsor
- Université de Sherbrooke
- Sponsor type
- University, hospital or other
- Collaborators
- Société des Produits Nestlé (SPN)
- Responsible party
- Sponsor
- Investigators
- Stephen Cunnane, Ph.D., Principal investigator, Université de Sherbrooke
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04322461
- Sponsor's protocol ID
- 2020-3436
- Acronym
- PARKA
- Status last verified
- May 2025
- First submitted
- 24 Mar 2020
- Last updated
- 3 Jun 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 3 Jun 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effect of Exercise, Endocannabinoids and Ketones on Cerebral Metabolism in a Cognitive Disorders Population : Pilot Project PARKA
- ClinicalTrials.gov ID
- NCT04322461
- Acronym / sponsor ID
- PARKA / 2020-3436
- Conditions
- Parkinson Disease, Alzheimer Disease
- Keywords
- Alzheimer, Parkinson, Ketones, medium chain triglycerides, cognition, brain
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 14 participants (actual)
- Lead sponsor
- Université de SherbrookeUniversity, hospital or other
- Collaborators
- Société des Produits Nestlé (SPN)
- Study start
- 1 May 2022 (actual)
- Primary completion
- 27 May 2024 (actual)
- Study completion
- 27 May 2024 (actual)
- First posted
- 26 Mar 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
A two months intervention in which two groups of cognitive disorders, Parkinson and Alzheimer's disease, will receive 50g/day of a commercial MCT supplement combined with supervised aerobic exercise 3 times/week. Cognition and ketones will be assess before and after the intervention, along with endocannabinoids plasma concentrations.
Study design
- Primary purpose
- Basic science
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Parkinson disease | Experimental | Dietary Supplement: Betaquik MCT supplement2 months intervention with 50g/day of a commercial MCT supplement combine with supervised aerobic exercise 3x/week. |
| Alzheimer's disease | Experimental | Dietary Supplement: Betaquik MCT supplement2 months intervention with 50g/day of a commercial MCT supplement combine with supervised aerobic exercise 3x/week. |
Who may qualify
- Ages
- 60 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Alzheimer's or parkinson disease diagnostic
- Stable medication associated with the disease
- Able to consent
- Presence of an accompanying person for the first and last visit.
- Ability to read and talk in French
Key exclusion criteria (10 listed)
- MMSE < 20
- MCT or coconut oil supplementation
- Coconut allergy
- Cannabis, THC or CBD consumption
- Excessive alcohol consumption
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Betaquik MCT supplement50g/day divided in 3. Breakfast, lunch and dinner | Dietary supplement | Alzheimer's disease, Parkinson disease |
Primary outcome
Cognition
Time frame: 2 months, evaluation before and after intervention
Measure of cognition with CANTAB
Ketones
Time frame: 2 months, evaluation before and after intervention
Measurement of ketones concentrations
1 secondary outcome
Endocannabinoids
Time frame: 2 months, evaluation before and after intervention
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 3 Jun 2025.
- Individual participant dataSharing planned: No
Related trials for Parkinson Disease
Not yet recruitingPhase 1/2
STAR0602 With Nivolumab in Non Small Cell Lung Cancer and in Metastatic Castrate-Resistant Prostate Cancer, and STAR0602 Alone in Thymic Carcinoma
NSCLC, Non-Small Cell Lung Cancer
Enrolling by invitationObservational study
Early Molecular Biomarkers for Differentiating Parkinsonian Syndromes
PARKINSON DISEASE (Disorder), Atypical Parkinsonism
RecruitingPhase 3
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
Cervical Cancer
Active, not recruitingPhase 1/2
Clinical Safety and Efficacy of Umbilical Cord Mesenchymal Stromal Cells-derived Exosomes in Patients With Parkinson's Disease
Parkinson Disease (PD)
Active, not recruitingObservational study
Adaptive DBS to Offset STN Dysregulation During Exercise in PD
Parkinson Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Stephen Cunnane, Ph.D. principal investigator
Université de Sherbrooke
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Betaquik MCT supplement in people with Parkinson Disease and Alzheimer Disease, run by Université de Sherbrooke at 1 site in Canada.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 3 Jun 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Cognition (time frame: 2 months, evaluation before and after intervention). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Jun 2025.